MDxHealth Announces Agreement with HIFU CLINIC Prostate Cancer Center for Distribution of SelectMDx in Poland

Further broadens reach of SelectMDx(TM) for Prostate Cancer in Europe

IRVINE, CA, and HERSTAL, BELGIUM - October 19, 2016 - MDxHealth SA (Euronext: MDXH.BR) a multinational healthcare company that provides actionable epigenetic information to personalize the diagnosis and treatment of urologic cancers, today announced an agreement with the HIFU CLINIC Prostate Cancer Center (HIFU CLINIC) for distribution of its SelectMDx(TM) for Prostate Cancer liquid biopsy assay throughout Poland. HIFU CLINIC will be the second distributor of SelectMDx in Poland.

Marek Filipek, MD, PhD, HIFU CLINIC Medical Director, stated: "Bringing the SelectMDx assay to the Polish market is a turning point in providing an advanced prostate cancer diagnostic decision tool that is both sensitive and specific to Polish Patients and their Physicians. The well-validated, non-invasive SelectMDx liquid biopsy test stands out in a growing field of yet unproven tools. Early identification of patients at risk for clinically significant prostate cancer is the key to accurate patient selection for prostate biopsy, with likely benefit to long term clinical outcomes."

"We are very pleased to announce our collaboration with HIFU CLINIC, whose High Intensity Focused Ultrasound (HIFU) Clinic is the first and only Polish center dedicated entirely to the comprehensive diagnostics and modern treatment of prostate cancer. SelectMDx will perfectly complement HIFU CLINIC's cutting edge diagnostic methods and procedures," commented Dr. Jan Groen, CEO of MDxHealth. "We believe this key partnership will help us improve awareness and widen access to SelectMDx throughout Poland."

About SelectMDx for Prostate Cancer

Of the nearly 2 million prostate biopsies performed each year, less than a third find cancer. Most of these men could have avoided a painful and invasive prostate biopsy procedure, with its associated complications and costs. SelectMDx for Prostate Cancer is a proprietary urine-based, molecular diagnostic test that offers a non-invasive 'liquid biopsy' method to assess a man's risk for prostate cancer. SelectMDx helps identify men at increased risk of harbouring aggressive, potentially lethal, prostate cancer who may benefit most from a prostate biopsy and earlier detection. The test delivers a negative predictive value (NPV) of 98% for clinically significant disease, helping to reduce unnecessary MRI procedures and invasive prostate biopsies by approximately 50%, thereby reducing healthcare costs.

About HIFU CLINIC Prostate Cancer Center

HIFU CLINIC Prostate Cancer Center is a unique private initiative dedicated to bringing innovative medical care solutions in diagnostics and therapy to the global patient base in cooperation with VEDI CLINIC Men's Health Clinic and AMEDS Medical Center. The Group is an experienced regional leader in the global medical tourism market in regard to, but not limited to, Men's Health. HIFU CLINIC Prostate Cancer Center and VEDI CLINIC Men's Health Clinic serve as providers of advanced diagnostic and treatment options to prostate cancer and erectile dysfunction patients. For more information visit: www.hifuclinic.eu or follow us on Twitter https://twitter.com/hifuclinic.

About MDxHealth